2018 国际意见书:恰当应用uricosurics和雷西纳德

2018-09-22 国外风湿免疫科相关专家小组 Clin Rheumatol. 2018 Sep 22.

在过去的70年里,痛风治疗的降尿酸药物由仅有4种,包括在2002年才开始应用的强效嘌呤氧化酶抑制剂非布索坦。在许多国家,在目前还没有应用Uricosurics类药物例如丙磺舒和苯溴马隆。本文主要介绍了恰当应用uricosurics类药物和雷西纳德的相关内容。

中文标题:

2018 国际意见书:恰当应用uricosurics和雷西纳德

英文标题:

International position paper on the appropriate use of uricosurics with the introduction of lesinurad.

发布日期:

2018-09-22

简要介绍:

在过去的70年里,痛风治疗的降尿酸药物由仅有4种,包括在2002年才开始应用的强效嘌呤氧化酶抑制剂非布索坦。在许多国家,在目前还没有应用Uricosurics类药物例如丙磺舒和苯溴马隆。本文主要介绍了恰当应用uricosurics类药物和雷西纳德的相关内容。

拓展指南:痛风相关指南:

相关资料下载:
[AttachmentFileName(sort=100, fileName=2018 国际意见书:恰当应用uricosurics和雷西纳德)] GetToolGuiderByIdResponse(projectId=1, id=b03b11c0016a665d, title=2018 国际意见书:恰当应用uricosurics和雷西纳德, enTitle=International position paper on the appropriate use of uricosurics with the introduction of lesinurad., guiderFrom=Clin Rheumatol. 2018 Sep 22., authorId=null, author=, summary=在过去的70年里,痛风治疗的降尿酸药物由仅有4种,包括在2002年才开始应用的强效嘌呤氧化酶抑制剂非布索坦。在许多国家,在目前还没有应用Uricosurics类药物例如丙磺舒和苯溴马隆。本文主要介绍了恰当应用uricosurics类药物和雷西纳德的相关内容。 , cover=, journalId=null, articlesId=null, associationId=893, associationName=国外风湿免疫科相关专家小组, associationIntro=null, copyright=0, guiderPublishedTime=Sat Sep 22 00:00:00 CST 2018, originalUrl=, linkOutUrl=, content=<div>在过去的70年里,痛风治疗的降尿酸药物由仅有4种,包括在2002年才开始应用的强效嘌呤氧化酶抑制剂非布索坦。在许多国家,在目前还没有应用Uricosurics类药物例如丙磺舒和苯溴马隆。本文主要介绍了恰当应用uricosurics类药物和雷西纳德的相关内容。</div> <div><br> </div>拓展指南:<strong>与<font color=red>痛风</font>相关指南:</strong><br><ul><li><a href="http://www.medsci.cn/guideline/show_article.do?id=8efc91c0015a94bd" title="2018 台湾多学科共识:痛风及高尿酸血症的管理" target=_blank>2018 台湾多学科共识:痛风及高尿酸血症的管理</a></li> <li><a href="http://www.medsci.cn/guideline/show_article.do?id=ce5591c001a4e8bb" title="【干货】痛风病最权威的指南汇总" target=_blank>【干货】痛风病最权威的指南汇总</a></li> <li><a href="http://www.medsci.cn/guideline/show_article.do?id=5881f1c001a45481" title="2017 BSR指南:痛风管理" target=_blank>2017 BSR指南:痛风管理</a></li> <li><a href="http://www.medsci.cn/guideline/show_article.do?id=63b981c001a449e2" title="2016 痛风治疗目标建议" target=_blank>2016 痛风治疗目标建议</a></li> <li><a href="http://www.medsci.cn/guideline/show_article.do?id=5172e1c001a255ab" title="2016年痛风治疗理念和治疗建议的更新" target=_blank>2016年痛风治疗理念和治疗建议的更新</a></li> 更多信息请点击:<a href="http://www.medsci.cn/guideline/list.do?q=%E7%97%9B%E9%A3%8E" target=_blank>有关痛风更多指南</a></ul>, tagList=[TagDto(tagId=101424, tagName=uricosurics), TagDto(tagId=81320, tagName=雷西纳德), TagDto(tagId=1530, tagName=痛风), TagDto(tagId=81321, tagName=降尿酸类药物)], categoryList=[CategoryDto(categoryId=15, categoryName=风湿免疫科, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=null, articleKeyword=null, articleKeywordNum=null, guiderKeywordId=null, guiderKeyword=null, guiderKeywordNum=null, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=其他, guiderLanguage=0, guiderRegion=0, opened=0, paymentType=null, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=6765, appHits=49, showAppHits=0, pcHits=5177, showPcHits=2411, likes=108, shares=5, comments=3, approvalStatus=1, publishedTime=Wed Oct 03 00:19:53 CST 2018, publishedTimeString=2018-09-22, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=1, createdBy=null, createdName=qiushida2, createdTime=Wed Oct 03 00:19:53 CST 2018, updatedBy=null, updatedName=null, updatedTime=Sat Jan 06 22:03:42 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=100, fileName=2018 国际意见书:恰当应用uricosurics和雷西纳德)])
2018 国际意见书:恰当应用uricosurics和雷西纳德
下载请点击:
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=347855, encodeId=f3e134e85577, content=谢谢了谢谢!, beContent=null, objectType=guider, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=30331616752, createdName=txqjm, createdTime=Thu Oct 04 06:25:35 CST 2018, time=2018-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=347749, encodeId=82c334e749aa, content=谢谢,学习了~, beContent=null, objectType=guider, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/nmoH3FVKe8KYYzm5OrpnZastaKg0jKDyvlVBp8RUZUBgynaVPQ86l6DbaqohIM3eIsowIy6V53q5n5mYuyzD6w/132, createdBy=aac72353870, createdName=122b87b4m49(暂无昵称), createdTime=Wed Oct 03 09:46:26 CST 2018, time=2018-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=347710, encodeId=1c1e34e7107b, content=谢谢了,学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=30331616752, createdName=txqjm, createdTime=Wed Oct 03 06:47:02 CST 2018, time=2018-10-03, status=1, ipAttribution=)]
    2018-10-04 txqjm

    谢谢了谢谢!

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=347855, encodeId=f3e134e85577, content=谢谢了谢谢!, beContent=null, objectType=guider, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=30331616752, createdName=txqjm, createdTime=Thu Oct 04 06:25:35 CST 2018, time=2018-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=347749, encodeId=82c334e749aa, content=谢谢,学习了~, beContent=null, objectType=guider, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/nmoH3FVKe8KYYzm5OrpnZastaKg0jKDyvlVBp8RUZUBgynaVPQ86l6DbaqohIM3eIsowIy6V53q5n5mYuyzD6w/132, createdBy=aac72353870, createdName=122b87b4m49(暂无昵称), createdTime=Wed Oct 03 09:46:26 CST 2018, time=2018-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=347710, encodeId=1c1e34e7107b, content=谢谢了,学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=30331616752, createdName=txqjm, createdTime=Wed Oct 03 06:47:02 CST 2018, time=2018-10-03, status=1, ipAttribution=)]
    2018-10-03 122b87b4m49(暂无昵称)

    谢谢,学习了~

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=347855, encodeId=f3e134e85577, content=谢谢了谢谢!, beContent=null, objectType=guider, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=30331616752, createdName=txqjm, createdTime=Thu Oct 04 06:25:35 CST 2018, time=2018-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=347749, encodeId=82c334e749aa, content=谢谢,学习了~, beContent=null, objectType=guider, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/nmoH3FVKe8KYYzm5OrpnZastaKg0jKDyvlVBp8RUZUBgynaVPQ86l6DbaqohIM3eIsowIy6V53q5n5mYuyzD6w/132, createdBy=aac72353870, createdName=122b87b4m49(暂无昵称), createdTime=Wed Oct 03 09:46:26 CST 2018, time=2018-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=347710, encodeId=1c1e34e7107b, content=谢谢了,学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=30331616752, createdName=txqjm, createdTime=Wed Oct 03 06:47:02 CST 2018, time=2018-10-03, status=1, ipAttribution=)]
    2018-10-03 txqjm

    谢谢了,学习

    0